SRRM4 Drives Neuroendocrine Transdifferentiation of Prostate Adenocarcinoma Under Androgen Receptor Pathway Inhibition.

Yinan Li,Nilgun Donmez,Cenk Sahinalp,Ning Xie,Yuwei Wang,Hui Xue,Fan Mo,Himisha Beltran,Martin Gleave,Yuzhuo Wang,Colin Collins,Xuesen Dong

European Urology（2017）

引用 139|浏览22

暂无评分

摘要

The incidence of neuroendocrine prostate cancer (NEPC) has become more prevalent with wider applications of next-generation antiandrogens. SRRM4 was identified and validated as a driver for NEPC and thus has potential to be a therapeutic target to prevent NEPC progression.

查看译文

关键词

Neuroendocrine prostate cancer,AR inhibition,SRRM4,Alternative RNA splicing

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要